TYPE OF POSTMENOPAUSAL HORMONE USE AND RISK OF BREAST-CANCER - 12-YEAR FOLLOW-UP FROM THE NURSES HEALTH STUDY

被引：100

作者：

COLDITZ, GA

STAMPFER, MJ

WILLETT, WC

HUNTER, DJ

MANSON, JE

HENNEKENS, CH

ROSNER, BA

SPEIZER, FE

机构：

来源：

CANCER CAUSES & CONTROL | 1992年 / 3卷 / 05期

关键词：

BREAST CANCER; COHORT STUDY; ESTROGENS; PROGESTINS; NURSES HEALTH STUDY; USA;

D O I：

10.1007/BF00051356

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

We prospectively examined the use of hormone replacement therapy in relation to breast cancer incidence in a cohort of women 30 to 55 years of age in 1976. During 12 years of follow-up (480,665 person-years) among postmenopausal women, 1,050 incident cases of breast cancer were documented. Overall, past users of replacement estrogen were not at increased risk. After adjustment for established risk factors, type of menopause, age at menopause, and current age, the rate ratio (RR) was 0.91, 95 percent confidence interval (CI) = 0.78-1.07. The risk of breast cancer was elevated significantly among current users (RR = 1.33, CI = 1.12-1.57); after adjusting for age, we observed no evidence of increasing risk with increasing duration of use among current users (P trend = 0.41), or among past users (P trend = 0.46). Women currently using unopposed estrogen (RR = 1.42, CI = 1.19-1.70), estrogen and progesterone (RR = 1.54, CI = 0.99-2.39), or progesterone alone (RR = 2.52, CI = 0.66-9.63), were all at increased risk of breast cancer compared with never users. These data suggest that long-term past use of estrogen replacement therapy is not related to risk, that current estrogen use increases risk of breast cancer to a modest degree, and that the addition of progesterone does not remove the increased risk observed with current use of unopposed estrogen.

引用

页码：433 / 439

页数：7

共 17 条

[1]

Colditz G.A., Stampfer M.J., Willett W.C., Hennekens C.H., Rosner B., Speizer F.E., Prospective study of estrogen replacement therapy and risk of breast cancer in postmenopausal women, JAMA, 264, pp. 2648-53, (1990)

[2]

Romieu I., Willett W.C., Colditz G.A., Et al., A prospective study of oral contraceptive use and the risk of breast cancer in women, JNCI, 81, pp. 1313-21, (1989)

[3]

London S.J., Colditz G.A., Stampfer M.J., Et al., A prospective study of relative weight, height, and risk of breast cancer, JAMA, 262, pp. 2853-8, (1989)

[4]

Colditz G.A., Stampfer M.J., Willett W.C., Et al., Reproducibility and validity of self-reported menopausal status in a prospective cohort of women, Am J Epidemiol, 126, pp. 319-25, (1987)

[5]

Stampfer M.J., Willett W.C., Speizer F.E., Et al., Test of the National Death Index, Am J Epidemiol, 119, pp. 837-9, (1984)

[6]

Mantel N., Chi-square test with one degree of freedom: extension of the Mantel-Haenszel procedure, J Am Stat Assoc, 56, pp. 690-700, (1983)

[7]

Cox D.R., Regression models and life-tables, JR Stat Soc (B), 34, pp. 187-220, (1972)

[8]

Gambrel R.D., Maier R.C., Sanders B.I., Decreased incidence of breast cancer in postmenopausal estrogen-progesterone users, Obstet Gynecol, 62, pp. 435-43, (1983)

[9]

Hayward R.A., Shapiro M.F., Freeman H.F., Corey C.R., Who gets screened for cervical and breast cancer? Results from a national survey, Arch Int Med, 148, pp. 1177-81, (1988)

[10]

Heath C.W., Funk D.J., Strickland R., Et al., Trends in screening mammography for women 50 years of age and older—Behavioral Risk Factor Surveillance System, 1987, MMWR, 38, pp. 137-40, (1989)

← 1 2 →